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To the Editor: In the November issue of Kidney International,
the 5-year experience of encapsulating peritoneal sclerosis
(EPS) in patients on peritoneal dialysis in a single center is
reported.1 This retrospective analysis, in which the EPS rate
was 3.3% overall, concluded that there were no differences in
peritoneal history or peritonitis rates between those who
developed EPS and those who did not. Careful radiological
monitoring of those on peritoneal dialysis for over 5 years,
with early catheter removal if peritoneal thickening was
detected, was recommended, with the suggestion that
tamoxifen may be beneficial.
This study is a valuable contribution to the literature on
EPS, but does not reflect the increasing evidence that a
fulminant variant of EPS can occur as a second phase
phenomenon immediately following the treatment of acute
bacterial peritonitis, and that rapid resolution is reported
with corticosteroid treatment alone.2
In this setting, an unrelenting acute inflammatory state
persists despite appropriate treatment for infective peritoni-
tis, and it may not be recognized that this is due to an acute
form of EPS rather than on-going sepsis. Aggressive
immunosuppression might be thought potentially hazardous
in these circumstances, but the greater risk is to miss the
diagnosis and opportunity for treatment. Corticosteroid
monotherapy appears particularly effective for these pa-
tients,2,3 who may comprise up to 25% of cases.4
The continuing high mortality of EPS suggests that this
subgroup of treatment-responsive patients may not be well
recognized by nephrologists. Future studies should seek to
determine if there is a clinical distinction between the acute
and chronic presentations of EPS in terms of pathogenesis
and response to immunosuppression.
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Racial differences in response to
cinacalcet as a treatment for
uremic hyperparathyroidism
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To the Editor: In a recent issue of Kidney International,
Martin et al.1 reported the results of a randomized controlled
trial in which parathyroid hormone (PTH) levels were
compared for 205 patients with uremic hyperparathyroidism
treated with cinacalcet versus 205 patients treated with
placebo. We believe that this analysis may have obscured
important PTH outcomes for black subjects.
In a sample of dialysis patients, one of us (AG) reported
that average PTH levels were approximately 650 pg/ml in
black subjects and 350 pg/ml in white subjects, after adjusting
for age, sex, diabetes, serum calcium, and phosphorus.2 In
multivariate regression analysis, black background was the
strongest independent correlate of maximum PTH.
Severe uremic hyperparathyroidism may not lead to severe
bone disease in black subjects, because black subjects may
have a relative resistance to PTH action as suggested by
decreased Gla protein and bone turnover.3 Based on studies
mostly among white subjects, PTH level of 150–300 pg/ml is
optimal in end-stage renal disease.4 Because treating black
subjects with parathyroid disease by these guidelines may be
inappropriate, it is critical to examine racial differences in
uremic hyperparathyroidism and response to PTH. Unfortu-
nately, the Martin et al. trial compared white subjects with a
pooled group of black subjects and ‘others’. If the ‘other’
group did not have PTH levels as elevated as those of black
subjects, collapsing these subjects into one category would
have created a downward bias in the analysis – thus obscuring
the clinical relevance of the findings for black patients with
uremic hyperparathyroidism. We recommend repeating the
analysis without collapsing the black people and ‘other’
groups.
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